Navigation Links
Final Patient Completes Prosonix' Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Date:8/16/2013

inhaler (pMDI) in male and female patients diagnosed with moderate or severe COPD; 37 patients were entered into the study and 33 completed all five dosing sessions.

The primary endpoint of the study is improved lung function as measured by Forced Expiratory Volume in one second (FEV1) area under the curve from time zero to 24 hours post dose. Multiple secondary physiological (lung function) and pharmacokinetic endpoints are also being evaluated. Top-line results are expected in early 2014 and will form the basis of the future clinical development of PSX1002. For more information, see http://www.clinicaltrials.gov.

Notes for Editors

About Prosonix        http://www.prosonix.co.uk

Prosonix is an innovative speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines by design.

Prosonix' ultrasonic particle engineering technology enables it to design and engineer mono and combination drug particles that precisely meet the specific requirements for inhalation, delivering assured formulation performance using simple, cost-effective devices for a range of generic, super-generic and novel products.

Prosonix' in-house pipeline focuses on near- and long-term opportunities, and is further complimented by a select number of partnered respiratory programs. The in-house pipeline includes:

  • PSX1001/PSX1050, a directly substitutable generic version of fluticasone propionate, a potent inhaled corticosteroid (ICS) monotherapy, for asthma and chronic obstructive pulmonary disease (COPD) in pressurised metered dose inhaler (pMDI),
  • PSX2005, a directly substitutable generic version of a leading ICS/long-acting beta agonist (LABA) combination in development for asthma and COPD in pMDI,
  • PSX1002, a drug-only proprietary formulation of glycop
    '/>"/>

SOURCE Prosonix
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cadence Pharmaceuticals Comments on USPTOs Non-Final, Initial Office Action on Reexamination of Patent
2. Accelerate Diagnostics Announces Final Results of Rights Offering
3. EpiCept Stockholders Overwhelmingly Approve Final Conditions to Merger with Immune Pharmaceuticals Ltd.
4. Accelerate Diagnostics Announces Final Terms of Rights Offering
5. Non-Toxic, Non-Surgical Medical Cancer Therapies Finally Available in the U.S.
6. Discovery Labs Presents Final Assessment in a Series of Pharmacoeconomic Analyses that Explore Impact of Reintubation on Healthcare Costs
7. Finalists Announced for Israel Brain Technologies Million Dollar Global B.R.A.I.N. Prize
8. Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results
9. Is There Finally A Way To Stop Severe Excessive Sweating?
10. Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
11. Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015 ... of cartilage, cellular, bone, skin and soft-tissue allografts ... to advance patient healing, today announced that AlloWrap® ... been moved to the high-cost reimbursement category. ... reach doctors and their patients," said Kimberly ...
(Date:5/28/2015)... , May 28, 2015 ... announced the addition of the "United States ... report to their offering.      (Logo: ... adhesives in the United States ... 2020 Medical device manufacturers across ...
(Date:5/28/2015)... 2015 KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO ... Martell , to the position of Executive Chairman. Mr. ... Board of Directors. In this new role, he will ... refine and execute on the strategic plan to transition ... for orphan oncology indications with high unmet medical need. ...
Breaking Medicine Technology:AlloSource Announces Milestone In Reimbursement For AlloWrap DS 2United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 2United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 3KaloBios Appoints Ronald A. Martell Executive Chairman 2KaloBios Appoints Ronald A. Martell Executive Chairman 3KaloBios Appoints Ronald A. Martell Executive Chairman 4KaloBios Appoints Ronald A. Martell Executive Chairman 5
... From today, an innovative non-drug, non-invasive treatment ... all hypertensive patients on NHS prescription. RESPeRATE is an ... When used for just 15 minutes a day, at ... significant, all-day blood pressure reduction beyond that seen with ...
... Therapeutics, Inc. (NASDAQ: HALO ) today presented ... tolerability study of HTI-501 (an investigational, conditionally active recombinant ... International Academy of Cosmetic Dermatology in Cancun, Mexico. Data ... portion of the clinical trial. The Phase 1/2 trial ...
Cached Medicine Technology:NHS Makes £200 Non-Drug Hypertension Treatment Device Available on Prescription 2NHS Makes £200 Non-Drug Hypertension Treatment Device Available on Prescription 3NHS Makes £200 Non-Drug Hypertension Treatment Device Available on Prescription 4HTI-501 Data Support Commencement of Phase 2 Portion of Clinical Trial 2HTI-501 Data Support Commencement of Phase 2 Portion of Clinical Trial 3
(Date:5/28/2015)... MA (PRWEB) May 28, 2015 Workers’ compensation ... the typical state, a recent study by the Workers ... falling over a three-year period. , The WCRI study, ... in which workers missed seven days or more of work ... months, the average 2011 Michigan claim was 4 percent lower ...
(Date:5/28/2015)... Ticket Down is a reputable source of presale tickets ... Argentina in early September. , Two of the best ... pitch at AT&T Stadium in Arlington/Dallas, TX. Mexico and Argentina ... Tuesday, September 8th at 9 p.m. The match will feature ... some of the most loved players in the entire sport. ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 According ... ( http://www.idataresearch.com ), the shoulder reconstruction device market, ... small bone & joint market in 2014. This ... arthroplasty procedures in the U.S. due to increased ... device technology resulting in greater patient outcomes. Therefore, ...
(Date:5/28/2015)... The connected car is gaining more traction with ... have some iteration of a connected offering in the ... companies as the data collected can be used to ... (UBI). This is the primary reason that 800+ senior ... Conference & Exhibition. , Andrew Pym, TU Automotive’s ...
(Date:5/28/2015)... lifeIMAGE announced today that it ... by Cambia Health Solutions (Portland, Ore.), a ... care by creating a person-focused and economically sustainable system. ... exchanging medical imaging, will use this financing to expand ... of its network capabilities and implement the next phases ...
Breaking Medicine News(10 mins):Health News:Michigan Workers’ Compensation Costs Lower Than Most States, Says WCRI Study 2Health News:Mexico vs. Argentina Tickets at AT&T Stadium: Ticket Down Slashes Ticket Prices on Argentina vs. Mexico Presale Tickets at AT&T Stadium for 9/8/15 Friendly Match 2Health News:Mexico vs. Argentina Tickets at AT&T Stadium: Ticket Down Slashes Ticket Prices on Argentina vs. Mexico Presale Tickets at AT&T Stadium for 9/8/15 Friendly Match 3Health News:DePuy Synthes and Biomet Lead Fastest Growing U.S. Shoulder Reconstruction Device Market 2Health News:DePuy Synthes and Biomet Lead Fastest Growing U.S. Shoulder Reconstruction Device Market 3Health News:TU-Automotive: North America’s Leading Insurers Head to Chicago as Connected Car Motor Insurance Shifts up a Gear 2Health News:TU-Automotive: North America’s Leading Insurers Head to Chicago as Connected Car Motor Insurance Shifts up a Gear 3Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 2Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 3Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 4
... million in the latest round of National Health and ... ever NHMRC funding amount for the greatest number of ... health and medical research grants today. , Monash University ... 62 individual projects, including: , $1.8 million ...
... Satyam Computer,Services Ltd. (NYSE: SAY ), a ... reported US GAAP results for its second,quarter, which ... Despite a challenging market that impacted several key ... exceeded its guidance in,the second quarter. Revenue was ...
... Health Message to Austin,s American,Heart Association Heart Walk, ... was the leading,cause of death among Texans in ... People with heart disease are at an increased ... flu. Therefore, the,U.S. Centers for Disease Control and ...
... Kicks Off Regional Expansion With Mobile Healthy,Living Experience ... World of Grains brand announced today,their expansion ... brand,will host a Mobile Healthy Living Experience at ... of making simple, better decisions,to improve their lifestyle ...
... Services; Kathleen A. Walsh named VP, Product Management; Gilbert ... for team to commercialize and support initial ... of NewCardio,s platform technology, SANTA CLARA, Calif., Oct. 17 ... services company, today,announced the hiring of three key executives to ...
... Cohera Medical Inc. today announced,it has secured $16.1 ... ongoing,development of TissuGlu(R), a novel surgical adhesive for ... led by Bradford Capital Partners, included,participation from existing ... financing provides the company with sufficient capital to ...
Cached Medicine News:Health News:Monash wins $32m for health and medical research 2Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 2Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 3Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 4Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 5Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 6Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 7Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 8Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 9Health News:Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets 10Health News:Huston Street Joins Mended Hearts with an Important Heart Health Message: Get Your Flu Shot! 2Health News:Huston Street Joins Mended Hearts with an Important Heart Health Message: Get Your Flu Shot! 3Health News:World of Grains(TM) - The Cookie That's One Bite Better Comes to a Store Near You 2Health News:World of Grains(TM) - The Cookie That's One Bite Better Comes to a Store Near You 3Health News:NewCardio Announces New Client Services Team 2Health News:NewCardio Announces New Client Services Team 3Health News:NewCardio Announces New Client Services Team 4Health News:Cohera Medical Secures $16.1 Million in Series B Financing 2
... macular health. Snellen charts available ... Easy to mount on most ... in a few minutes. Rapid ... Retinal vision testing without refraction ...
Eye Q Lite is ideal for color and red-free imaging used in general clinical and optometric casework such as anterior segmenting and diabetic screening....
The Genesis Camera meets the needs of those with specific requirements that cannot be met by a conventional 'chinrest' type camera....
The quick access to diabetic screening, panoramic images of the retina including peripheral area are available by using easy, semi automatic guidance of peripheral fixation....
Medicine Products: